As the Trump administration works to implement a “most-favored nation” policy, Lilly said it’s “rebalancing” drug prices to ...

The result marks the latest failure for a microbiome therapy in inflammatory bowel disease, which has long been a top target ...

Liquidating its stake in Arrowhead helps Sarepta cover a milestone payment and secure what one analyst described as ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

The startup agreed to pay Fosun Pharma as much as $645 million for a drug in testing for multiple lung conditions, including ...

Padcev, an antibody-drug conjugate which Pfizer acquired via its $43 billion Seagen deal, could help people who don’t qualify ...

A regimen involving the company’s shot failed a Phase 3 trial “by a hair,” an executive said, leading the company to believe ...

The complex settlement, which hands payouts and royalties to CureVac and partner GSK, comes as BioNTech is inching toward an ...

Brinsupri, which Insmed acquired from AstraZeneca nearly a decade ago, is the first treatment for bronchiectasis that’s not ...

The spinout, known as Celea Therapeutics, will advance what’s designed to be an improved version of the drug pirfenidone for ...

The newly announced program targeting domestic manufacturing is the latest Trump administration move to ramp up drugmaking in ...

With a strong launch underway for a bladder cancer gene therapy, Ferring is finding the kind of commercial success that’s ...